Jan 26 (Reuters) - Moderna Inc said on Wednesday it
had dosed the first participant in a mid-stage study testing its
Omicron-specific booster vaccine candidate.
The company also reported data showing that neutralizing
antibodies against the Omicron COVID-19 variant declined
6.3-fold from peak levels six months after a third booster dose
of its vaccine but remained detectable.
(Reporting by Amruta Khandekar; Editing by Devika Syamnath)